Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
2021-06-16 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
Thelen, M.; Wennhold, K.; Lehmann, J.; Garcia-Marquez, M.; Klein, S.; Kochen, E. & Lohneis, P. et al. (2021)
npj Precision Oncology, 5(1) art. 52. DOI: https://doi.org/10.1038/s41698-021-00196-x
Documents & Media
Details
- Authors
- Thelen, Martin; Wennhold, Kerstin; Lehmann, Jonas; Garcia-Marquez, Maria; Klein, Sebastian; Kochen, Elena; Lohneis, Philipp; Lechner, Axel; Wagener-Ryczek, Svenja; Plum, Patrick Sven; Velazquez Camacho, Oscar; Pfister, David; Dörr, Fabian; Heldwein, Matthias; Hekmat, Khosro; Beutner, Dirk ; Klussmann, Jens Peter; Thangarajah, Fabinshy; Ratiu, Dominik; Malter, Wolfram; Merkelbach-Bruse, Sabine; Bruns, Christiane Josephine; Quaas, Alexander; Bergwelt-Baildon, Michael von; Schlößer, Hans A.
- Abstract
- Abstract The immune response against cancer is orchestrated by various parameters and site-dependent specificities have been poorly investigated. In our analyses of ten different cancer types, we describe elevated infiltration by regulatory T cells as the most common feature, while other lymphocyte subsets and also expression of immune-regulatory molecules on tumor-infiltrating lymphocytes showed site-specific variation. Multiparametric analyses of these data identified similarities of renal and liver or lung with head and neck cancer. Co-expression of immune-inhibitory ligands on tumor cells was most frequent in colorectal, lung and ovarian cancer. Genes related to antigen presentation were frequently dysregulated in liver and lung cancer. Expression of co-inhibitory molecules on tumor-infiltrating T cells accumulated in advanced stages while T-cell abundance was related to enhanced expression of genes related to antigen presentation. Our results promote evaluation of cancer-specific or even personalized immunotherapeutic combinations to overcome primary or secondary resistance as major limitation of immune-checkpoint inhibition.
- Issue Date
- 16-June-2021
- Journal
- npj Precision Oncology
- eISSN
- 2397-768X
- Language
- English
- Sponsor
- Deutsche Krebshilfe (German Cancer Aid) https://doi.org/10.13039/501100005972